Journals / Van Tıp Dergisi / 2019 / Cilt: 26 - Sayı: 1

Demographic, clinical, and genetic evaluation of patients with suspected inherited thrombophilia

Genetik Trombozdan Şüphe Edilen Hastaların Demografik ve Klinik Değerlendirilmesi

Pages
103–108
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Heterozygous and homozygous FVL mutations and PG20210A mutation were associated with higher risk of venous thrombosis, while heterozygous MTHFR 677 mutation was associated with higher risk of arterial thrombosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectıve: Inherited and acquired disorders of hemostasis cause thrombophilia.
📊
Key Findings & Data:Materıals and Methods: Data pertaining to patients with suspected inherited thrombophilia who underwent genetic mutational analysis between September 1998 and December 2009 were retrospectively evaluated.
💡
Conclusion & Impact:Conclusion: Heterozygous and homozygous FVL mutations and PG20210A mutation were associated with higher risk of venous thrombosis, while heterozygous MTHFR 677 mutation was associated with higher risk of arterial thrombosis.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectıve: Inherited and acquired disorders of hemostasis cause thrombophilia. Thrombosis occurs earlier in individuals with multiple inherited hemostatic disorders. In this study, we aimed to evaluate the distribution of mutation types in patients with suspected heritable thrombophilia according to the presence of venous or arterial thrombosis. Materıals and Methods: Data pertaining to patients with suspected inherited thrombophilia who underwent genetic mutational analysis between September 1998 and December 2009 were retrospectively evaluated. Results: The study included a total of 394 patients suspected of having inherited thrombophilia due to the presence of venous thrombosis (66.5%) or arterial thrombosis (33.5%). Of these patients, 202 (51.3%) were female and the mean age was 45.49 ± 15.08 years. Evaluation of risk factors for venous and arterial thrombosis revealed that smoking history, metabolic syndrome, and genetic mutations were more common among patients with arterial thrombosis compared to those with venous thrombosis. Venous thrombosis was found to be associated with older age, immobility, and history of surgery and prior embolism. Heterozygous MTHFR 677 mutation was significantly more common among patients with arterial thrombosis. Heterozygous FVL, homozygous FVL, and PG20210A mutations were significantly more common in patients with venous thrombosis compared to those with arterial thrombosis. Conclusion: Heterozygous and homozygous FVL mutations and PG20210A mutation were associated with higher risk of venous thrombosis, while heterozygous MTHFR 677 mutation was associated with higher risk of arterial thrombosis.

Özet

Amaç: Genetik ve akkiz olarak gelişen hemostaz bozuklukları, tromboza yatkınlık meydana getirirler. Eğer kişide birden fazla genetik hemostaz bozukluğu varsa tromboz daha erken dönemde ortaya çıkmaktadır. Bu çalışmamızda, genetik trombozdan şüphe edilen venöz ve arteriyel tromboza göre mutasyon tiplerinin dağılımlarının değerlendirmesi amaçlanmıştır. Gereç ve Yöntem: Hastanemizde 1998 Eylül ve 2009 Aralık ayı içerisinde genetik trombozdan şüphe edilen ve genetik mutasyon testi istenmiş olan hastaların verileri retrospektif olarak sorgulandı. Bulgular: Çalışmamıza, venöz tromboz (%66,5) ve arteriyel tromboz (%33,5) nedeni ile trombofili için genetik yatkınlıktan şüphe edilen 394 hasta dahil edilmiştir. Hastaların, 202’si (%51,3) kadın ve yaş ortalamaları 45,49 ± 15,08 olarak bulunmuştur. Venöz ve arteriyel tromboz risk faktörlerine bakıldığında arteriyel trombozu olanlarda, sigara kullanım öyküsünün daha fazla olduğu, metabolik sendrom ve mutasyon varlığının venöz trombozu olanlara göre daha fazla olduğu görülmüşür. Venöz trombozu olanların ise daha yaşlı oldukları, immobilite, operasyon ve daha önceden emboli öyküsü olanlarda venöz trombozun daha sık olduğu görülmüştür Arteriyel trombozu olanlarda MTHFR 677 heterozigot mutasyonu istatistiksel anlamlı olarak daha fazla tespit edilmiştir. Venöz tromboz olanlarda ise FVL heterozigot, FVL homozigot, PG20210A mutasyonları arteriyel trombozu olanlara göre istatistiksel anlamlı olarak daha fazla tespit edilmiştir. Sonuç: Venöz trombozu olan hastalarda, FVL heterozigot, FVL homozigot ve PG20210A mutasyonunun, arteriyel trombozu olan hastalarda MTHFR 677 heterozigot mutasyonu varlığının arteriyel tromboz riskini artırdığı tespit edilmiştir.

🔖

Cite This Article

TAŞAR, P. T., KARAŞAHİN, Ö., ÖZDEMİR, Ö., ÇENELİ, S., TURGUT, N. H., DEMİRKAN, F. (2019). Demographic, clinical, and genetic evaluation of patients with suspected inherited thrombophilia. Van Tıp Dergisi, Cilt: 26 - Sayı: 1, 103–108. https://ajindex.com/articles/334499

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997; 78(1): 1-6
  2. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5(4): 692-699
  3. Kristensen SR, Andersen-Ranberg K, Bathum L, Jeune B. Factor V Leiden and venous thrombosis in Danish centenarians. Thromb Haemost 1998; 80(5): 860-861
  4. Eichinger S, Minar E, Hirschl M, Bialonczyk C, Stain M, Mannhalter C, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999; 81(1): 14-17
  5. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353(9159): 1167-1173
  6. Reitsma PH, Rosendaal FR. Past and future of genetic research in thrombosis. J Thromb Haemost 2007; 5: 264-269
  7. Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167(9): 935-943
  8. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83(5): 657-660
  9. Tracy RP. Hemostatic and inflammatory markers as risk factors for coronary disease in the elderly. Am J Geriatr Cardiol 2002; 11(2): 93-100
  10. Albers GW. Antithrombotic therapy for prevention and treatment of ischemic stroke. J Thromb Thrombolysis 2001; 12(1): 19-22
  11. Otten HM, Mathijssen J, ten Cate H, Soesan M, Inghels M, Richel DJ, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004; 164(2): 190-194
  12. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10(5): 502- 509
  13. Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 1992; 127(3): 310-313
  14. Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjonneland A, Overvad K. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost 2009; 7(8): 1297-1303
  15. Arteaga RB, Chirinos JA, Soriano AO, Jy W, Horstman L, Jimenez